Consolidated Statements of Convertible Redeemable Preferred Stock, Comprehensive Gain (Loss) and Stockholders' (Deficit) Equity (USD $)	Total	Preferred Stock	Common Stock	Additional Paid - In Capital	Deferred Compensation	Accumulated Other Comprehensive Income (Loss)	Deficit Accumulated During Development Stage
Balance at Oct. 15, 1992
Balance, shares at Oct. 15, 1992
Issuance of common stock and warrants, net of issuance costs of $1,928,421	56,458,546		115,168	56,343,378
Issuance of common stock and warrants, net of issuance costs of $1,928,421, shares			11,516,790
Issuance of common stock and warrants upon Merger	14,603,948		7,239	14,596,709
Issuance of common stock and warrants upon Merger, shares			723,947
Issuance of warrants in connection with debentures, net of issuance costs of $392,958	3,632,632			3,632,632
Issuance of warrants in connection with preferred series C stock issuance and related beneficial conversion feature, net of issuance costs of $590,890	3,736,789			3,736,789
Preferred stock, net of issuance costs of $4,078,821	25,584,456	2,296,355		23,288,101
Preferred stock, net of issuance costs of $4,078,821, shares		240,711
Conversion of Preferred Stock K and payment of interest, net of issuance costs of $27,664	6,179,186	(1,491,474)	15,538	7,655,122
Conversion of Preferred Stock K and payment of interest, net of issuance costs of $27,664, shares		(240,149.7)	1,553,749
Conversion of debentures and payment of interest, net of issuance costs of $307,265	4,847,420		3,171	4,844,249
Conversion of debentures and payment of interest, net of issuance costs of $307,265, shares			317,083
Conversion of preferred stock and modification of warrants		(3,501,539)	9,006	3,492,533
Conversion of preferred stock and modification of warrants, shares		(561.3)	900,646
Preferred stock conversion inducement	(600,564)			(600,564)
Amortization of preferred stock Series E beneficial conversion feature		2,696,658		(2,696,658)
Issuance of warrants in connection with Series E Stock, net of issuance costs of $278,426	2,049,297			2,049,297
Issuance of common stock in connection with cancellation of warrants			427	(427)
Issuance of common stock in connection with cancellation of warrants, shares			42,667
Accrual of dividends on preferred Series E stock	(573,597)			(573,597)
Deferred compensation related to stock options and warrants granted				804,607	(804,607)
Other	69,933		8	69,925
Other, shares			783
Exercise of warrants and options	7,596,439		11,850	7,584,589
Exercise of warrants and options, shares			1,185,039
Conversion of convertible debentures	988,591		313	988,278
Conversion of convertible debentures, shares			31,321
BCF on 10% convertible secured promissory notes	558,000			558,000
Share-based compensation	4,274,806			3,470,199	804,607
Modification of stock options	1,804,694			1,804,694
Issuance of common stock	48,725		3,040	45,685
Issuance of common stock, shares			304,009
Accretion of preferred stock	(4,327,679)			(4,327,679)
Comprehensive Income (Loss)
Net income (loss)	(143,503,529)						(143,503,529)
Balance at Dec. 31, 2006
Balance, shares at Dec. 31, 2006
Exercise of warrants and options	145,705		2,022	143,683
Exercise of warrants and options, shares			202,183
Conversion of convertible debentures	10,000,000		40,000	9,960,000
Conversion of convertible debentures, shares			4,000,000
BCF on 10% convertible secured promissory notes	1,880,000			1,880,000
Share-based compensation	1,665,155			1,665,155
Modification of stock options	5,614			5,614
Comprehensive Income (Loss)
Unrealized gain (loss) on marketable securities	9,310					9,310
Net income (loss)	(19,548,348)						(19,548,348)
Comprehensive income (loss)	(19,539,038)
Balance at Dec. 31, 2007	(22,414,471)		207,782	140,420,314		9,310	(163,051,877)
Balance, shares at Dec. 31, 2007			20,778,217
Exercise of warrants and options	2,541		11	2,530
Exercise of warrants and options, shares			1,100
Conversion of convertible debentures	120,000		480	119,520
Conversion of convertible debentures, shares			48,000
BCF on 10% convertible secured promissory notes	380,000			380,000
Share-based compensation	1,670,063			1,670,063
Issuance of common stock	1,085,275		5,718	1,079,557
Issuance of common stock, shares			571,806
Comprehensive Income (Loss)
Unrealized gain (loss) on marketable securities	(9,310)					(9,310)
Net income (loss)	(20,847,459)						(20,847,459)
Comprehensive income (loss)	(20,856,769)
Balance at Dec. 31, 2008	(40,013,361)		213,991	143,671,984			(183,899,336)
Balance, shares at Dec. 31, 2008			21,399,123
Share-based compensation	1,473,083			1,473,083
Issuance of common stock	2,002,000		41,565	1,960,435
Issuance of common stock, shares			4,156,522
Issuance of preferred stock	4,872,812	5,066,919		(192,107)			(2,000)
Issuance of preferred stock, shares		196,000
Comprehensive Income (Loss)
Net income (loss)	(10,776,937)						(10,776,937)
Comprehensive income (loss)	(10,776,937)
Balance at Dec. 31, 2009	(42,442,403)	5,066,919	255,556	146,913,395			(194,678,273)
Balance, shares at Dec. 31, 2009		196,000	25,555,645
Share-based compensation	61,722			61,722
Issuance of common stock			15,000	(15,000)
Issuance of common stock, shares			1,500,000
Buyback of common stock	(8,100)		(2,700)	(5,400)
Buyback of common stock, shares			(270,000)
Amortization of legal expenses	18,239	18,239
Accretion of preferred stock		343,000		(343,000)
Comprehensive Income (Loss)
Net income (loss)	512,419						512,419
Comprehensive income (loss)	512,419
Balance at Dec. 31, 2010	(47,286,281)	5,428,158	267,856	146,611,717			(194,165,854)
Balance, shares at Dec. 31, 2010		196,000	26,785,645
Conversion of convertible debentures	7,172,412		28,690	7,143,722
Conversion of convertible debentures, shares			2,868,965
Share-based compensation	834			834
Issuance of common stock-debt forgiveness	28,680		3,585	25,095
Issuance of common stock-debt forgiveness, shares			358,500
Buyback of common stock at $.0025 per share	(7,172)		(28,690)	21,518
Buyback of common stock at $.0025 per share, shares			(2,868,965)
Buyback of common stock	(11,084)		(11,084)
Buyback of common stock, shares			(1,108,425)
Forgiveness of accrued interest on convertible debt	6,132,499			6,132,499
Conversion of Series F Preferred to common stock		(4,600,000)	46,000	4,554,000
Conversion of Series F Preferred to common stock, shares		(184,000)	4,600,000
Forgiveness of accrued interest on note payable-Neurobiologics	195,807			195,807
Settlement of Neurobiologics note payable	999,000			999,000
Amortization of legal expenses	6,949	6,949
Accretion of preferred stock		(486,663)		486,663
Comprehensive Income (Loss)
Unrealized gain (loss) on marketable securities	(31,367)					(31,367)
Net income (loss)	(2,882,214)						(2,882,214)
Comprehensive income (loss)	(2,913,581)
Balance at Dec. 31, 2011	$ (30,602,223)	$ 348,444	$ 306,357	$ 166,170,855		$ (31,367)	$ (197,048,068)
Balance, shares at Dec. 31, 2011		12,000	30,635,720